Abstracts tagged "calcinosis"

Abstract Number: 2086 • 2013 ACR/ARHP Annual Meeting
Defining The Prevalence and Associated Risk Factors For Calcinosis In Adult Dermatomyositis Patients
Jessie Werner¹, Jason Liebowitz², Andrew L. Mammen³ and Lisa Christopher-Stine⁴, ¹Medicine, University of Maryland School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³NIAMS, NIH, Bethesda, MD, ⁴Medicine and Neurology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Calcinosis is known to be associated with junvenile dermatomyositis, but the prevalence and risk factors associated with the development of calcinosis in adult dermatomyositis…
Abstract Number: 679 • 2013 ACR/ARHP Annual Meeting
Validation Of a Novel Radiographic Scoring System For Calcinosis Affecting The Hands Of Patients With Systemic Sclerosis
Lorinda Chung¹, Antonia Maria Valenzuela Vergara², David Fiorentino³, Kate Stevens², Shufeng Li⁴, Jonathan Harris⁵, Charles E. Hutchinson⁶, Shervin Assassi⁷, Lorenzo Beretta⁸, Santhanam Lakshminarayanan⁹, Tatiana Rodriguez Reyna¹⁰, Christopher P. Denton¹¹, Rebecca G. Taillefer¹², Solene Tatibouet¹³, Ariane Herrick¹⁴ and Murray Baron¹⁵, ¹Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ²Stanford University School of Medicine, Stanford, CA, ³Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Dermatology, Stanford University School of Medicine, Palo Alto, CA, ⁵Salford Royal Hospital, Manchester, United Kingdom, ⁶Warwick Medical School, University of Warwick, Coventry, United Kingdom, ⁷Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁸Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ⁹Dept of Med/Div Rheum Diseases, University of Connecticut School of Medicine, Farmington, CT, ¹⁰Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, ¹¹Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ¹²University of Montreal, Montreal, QC, Canada, ¹³Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹⁴Musculoskeletal Research Group, University of Manchester, Salford, United Kingdom, ¹⁵Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Calcinosis affects approximately 25% of patients with systemic sclerosis (SSc) and is associated with substantial morbidity. There are currently no validated outcome measures…
Abstract Number: 228 • 2013 ACR/ARHP Annual Meeting
The Composition and Structure Of Calcifications In Juvenile Dermatomyositis Differs From Calcified Aortic Valves Removed From Adults Without JDM
Lauren M. Pachman^1,2, Gabrielle A. Morgan¹, Patrick M. McCarthy³, Anna Huskin³, S. Chris Malaisrie³, Lyudmila Spevak⁴, Stephen Doty⁴ and Adele Boskey⁴, ¹Cure JM Myositis Center, Ann & Robert H. Lurie Children's Hospital of Chicago Research Center, Chicago, IL, ²Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute, Chicago, IL, ⁴Hospital for Special Surgery, New York, NY
Background/Purpose: Juvenile Dermatomyositis (JDM) is a systemic vasculopathy, primarily involving the micro vasculature. Soft tissue calcification occurs in 15-30% of cases, and is associated with…
Abstract Number: 229 • 2012 ACR/ARHP Annual Meeting
Clinical Differences Between Adult and Juvenile Dermatomyositis Associated with Anti-NXP2 Autoantibodies
Sarah Tansley¹, Zoe Betteridge¹, Harsha Gunawardena², Lucy R. Wedderburn³, Hector Chinoy⁴, Robert G. Cooper⁵, Jiri Vencovsky⁶, Lenka Plestilova⁷, Ingrid E. Lundberg⁸, Katalin Danko⁹, Melinda Vincze¹⁰, Neil McHugh¹¹, UK JDRG¹² and EuMyoNet¹³, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Rheumatology, North Bristol NHS Trust, Bristol, United Kingdom, ³Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ⁴Rheumatology, The University of Manchester, Manchester, United Kingdom, ⁵Rheumatic Diseaes Center, Salford Royal Foundation Trust, Salford, United Kingdom, ⁶Institute of Rheumatology, Prague, Czech Republic, ⁷Institute of Rheumatology, Prague 2, Czech Republic, ⁸Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁹University of Debrecen, University of Debrecen, Debrecan, Hungary, ¹⁰University of Debrecen, University of Debrecen, Debrecen, Hungary, Debrecan, Hungary, ¹¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹²Institute of Child Health, London, United Kingdom, ¹³Rheumatology Unit, Stockholm, Sweden
Background/Purpose: Myositis specific antibodies (MSA) can divide dermatomyositis patients into distinct clinical subsets and help predict the risk of disease complications such as interstitial lung…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].